Background
Earlier SPIRIT percutaneous coronary intervention (PCI) trials with the XIENCE V everolimus-eluting stent (EES), including SPIRIT FIRST, II, III, and IV, met their prespecified primary and major secondary endpoints; however, they were restricted to patients with highly selected inclusion/exclusion criteria. The SPIRIT V Study provided an evaluation of EES performance in ‘real-world’ complex patient and lesion subsets in a global patient population. The aim of this analysis was to analyze outcomes of patients undergoing EES treatment of bifurcation lesions, a subset in which treatment is particularly challenging.
Methods
The registry arm of SPIRIT V enrolled 2700 patients outside the United States with de novo coronary artery lesions. Patients with coronary artery disease and artery morphology suitable to be optimally treated with a maximum of four planned stents (maximum of one, de novo, target lesion per native major epicardial vessel or side branch) were enrolled; lesion evaluation was per visual assessment. The outcomes of the 508 patients undergoing EES stenting of ≥1 bifurcation lesion were compared with those with no bifurcation lesion treated.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
